Johnson & Johnson Unveils First and Only TREMFYA® (guselkumab) for the Treatment of Crohn’s Disease
Johnson & Johnson has introduced TREMFYA® (guselkumab) as the first and only FDA-approved IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD).
TREMFYA® is a fully human monoclonal antibody that blocks IL-23, a cytokine involved in immune-mediated diseases, including Crohn's disease.
Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cure. It affects millions of people and is believed to be influenced by genetic, environmental, and immune system factors.
Symptoms can include abdominal pain, diarrhoea, rectal bleeding, weight loss, and fever. Current treatments aim to manage symptoms and improve the quality of life for those affected.
Currently, no other approved IL-23 inhibitor offers both subcutaneous and intravenous induction options for Crohn’s disease.
Approval was granted based on two Phase 3 clinical trials, which demonstrated that TREMFYA® significantly improved clinical remission and endoscopic outcomes over a 48-week period.
The treatment consists of a fully human monoclonal antibody that selectively blocks IL-23, a key cytokine involved in immune-mediated diseases, including Crohn’s disease. By targeting IL-23, TREMFYA® helps reduce inflammation and manage symptoms in patients with moderate to severe disease.
TREMFYA® is the first and only FDA-approved IL-23 inhibitor for Crohn’s disease, providing a novel therapeutic option for patients who have not responded to or cannot tolerate existing treatments.
